Cells were seeded in 96-well plates and treated with indicated concentrations of osimertinib, saracatinib or dasatinib alone or in combination for 48 hours. DMSO was used as control. Cell viability was measured using Cell Titer Glo (Promega) according to manufacturer’s instructions. The drug concentration giving 50% reduction in cell viability was used as a marker for drug effect.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.